Hepatic ceramides contribute to hyperglycemia and insulin resistance by inhibiting the action of Akt/PKB, disrupting insulin’s ability to suppress hepatic glucose production and inhibiting glycogen synthesis [105]. The gene discussed is AKT1; the disease is Hyperglycemia.